These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36641788)

  • 1. Letter: Ozanimod and latent tuberculosis.
    Alaskar D; AlMusa Z; AlAmeel T
    Aliment Pharmacol Ther; 2023 Feb; 57(3):353-354. PubMed ID: 36641788
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: ozanimod and latent tuberculosis-authors' reply.
    Zhang E; Christensen B
    Aliment Pharmacol Ther; 2023 Feb; 57(3):355-356. PubMed ID: 36641790
    [No Abstract]   [Full Text] [Related]  

  • 3. Hypertensive Emergency After Initiating Ozanimod: A Case Report.
    Choi DK; Rubin DT; Puangampai A; Cleveland N
    Inflamm Bowel Dis; 2022 Aug; 28(8):e114-e115. PubMed ID: 35212384
    [No Abstract]   [Full Text] [Related]  

  • 4. To eliminate tuberculosis, we must universally encourage treatment of its latent form.
    Schraufnagel DE
    Respirology; 2015 Aug; 20(6):851-4. PubMed ID: 26172202
    [No Abstract]   [Full Text] [Related]  

  • 5. Diagnosis and Treatment of Latent Tuberculosis Infection.
    Chitnis AS; Jaganath D; Gish RG; Wong RJ
    Am J Gastroenterol; 2021 Nov; 116(11):2155-2158. PubMed ID: 34382949
    [No Abstract]   [Full Text] [Related]  

  • 6. Discriminating between latent and active tuberculosis: the role of interleukin-2 as biomarker.
    Mamishi S; Pourakbari B; Marjani M; Bahador A; Mahmoudi S
    J Infect; 2015 Apr; 70(4):429-31. PubMed ID: 25562449
    [No Abstract]   [Full Text] [Related]  

  • 7. Ozanimod in Crohn's disease: a promising new player.
    Sleutjes JAM; de Vries AC; van der Woude CJ
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):791-792. PubMed ID: 32553150
    [No Abstract]   [Full Text] [Related]  

  • 8. Latent tuberculosis.
    Am Fam Physician; 2014 Jun; 89(11):Online. PubMed ID: 25077404
    [No Abstract]   [Full Text] [Related]  

  • 9. Ozanimod: First Approval.
    Lamb YN
    Drugs; 2020 Jun; 80(8):841-848. PubMed ID: 32385738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scaling up of latent tuberculosis infection treatment for close contacts of tuberculosis in Taiwan.
    Chan PC; Yang CH; Chang FY
    J Formos Med Assoc; 2011 Dec; 110(12):733-6. PubMed ID: 22351971
    [No Abstract]   [Full Text] [Related]  

  • 11. Ozanimod for Ulcerative Colitis.
    Senussi NH; Rakov N
    N Engl J Med; 2022 Jan; 386(2):194. PubMed ID: 35020994
    [No Abstract]   [Full Text] [Related]  

  • 12. Ozanimod for Ulcerative Colitis.
    Macaluso FS; Orlando A
    N Engl J Med; 2022 Jan; 386(2):194. PubMed ID: 35020993
    [No Abstract]   [Full Text] [Related]  

  • 13. Ozanimod for Ulcerative Colitis. Reply.
    Sandborn WJ; Danese S
    N Engl J Med; 2022 Jan; 386(2):194-195. PubMed ID: 35020995
    [No Abstract]   [Full Text] [Related]  

  • 14. Policy Implications of Mathematical Modeling of Latent Tuberculosis Infection Testing and Treatment Strategies to Accelerate Tuberculosis Elimination.
    Marks SM; Dowdy DW; Menzies NA; Shete PB; Salomon JA; Parriott A; Shrestha S; Flood J; Hill AN
    Public Health Rep; 2020; 135(1_suppl):38S-43S. PubMed ID: 32735183
    [No Abstract]   [Full Text] [Related]  

  • 15. Ozanimod for the Treatment of Ulcerative Colitis.
    Khanna R; Chande N; Marshall JK
    Gastroenterology; 2022 Jun; 162(7):2104-2106. PubMed ID: 35122762
    [No Abstract]   [Full Text] [Related]  

  • 16. Challenges in diagnosis and treatment of latent tuberculosis infection.
    Gupta KB
    Indian J Tuberc; 2012 Jan; 59(1):1-5. PubMed ID: 22670504
    [No Abstract]   [Full Text] [Related]  

  • 17. Ozanimod for the treatment of relapsing remitting multiple sclerosis.
    Rasche L; Paul F
    Expert Opin Pharmacother; 2018 Dec; 19(18):2073-2086. PubMed ID: 30407868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Latent tuberculosis infection: diagnostic tests and when to treat.
    Petersen E; Chakaya J; Jawad FM; Ippolito G; Zumla A
    Lancet Infect Dis; 2019 Mar; 19(3):231-233. PubMed ID: 30833050
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis.
    Swallow E; Patterson-Lomba O; Yin L; Mehta R; Pelletier C; Kao D; Sheffield JK; Stonehouse T; Signorovitch J
    J Comp Eff Res; 2020 Mar; 9(4):275-285. PubMed ID: 31948278
    [No Abstract]   [Full Text] [Related]  

  • 20. [Prevention of secondary tuberculosis in the contact tracing].
    Matsumoto K; Shimouchi A
    Kekkaku; 2011 Nov; 86(11):889-90. PubMed ID: 22295434
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.